Vulvovaginal pyoderma gangrenosum associated with rituximab use in 2 patients with rheumatoid arthritis
Jason R. Sotzen, MD, Erik J. Stratman, MD
JAAD Case Reports · 2021
doi:10.1016/j.jdcr.2021.02.013 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis occurring at a rate of 3-10 per million/year in the general population, with a higher frequency in women. Roughly half of the patients have an associated medical condition, with inflammatory bowel disease, hematologic disorders, and arthritis having the strongest associations.1 Vulvovaginal involvement is exceedingly rare, with few cases reported in the literature. A recent connection between rituximab use and vulvovaginal PG has been reported, with successful treatment using immunomodulatory medications.
Abstract licence: CC BY-NC-ND
References7
7 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.